Search
angiotensin II receptor type-2; AT2 (AGTR2)
Function:
- receptor for angiotensin II
- cooperates with MTUS1 to inhibit ERK2 activation & cell proliferation
- interacts with MTUS1
- AGTR2 may play a role in neuropathic pain
Structure: belongs to the G-protein coupled receptor 1 family
Compartment: cell membrane; multi-pass membrane protein
Expression:
- in adult, highly expressed in myometrium with lower levels in adrenal gland & fallopian tube
- very highly expressed in fetal kidney & intestine
Pharmacology:
- AGTR2 antagonist EMA401 may be useful for treating postherpetic neuralgia/neuropathic pain [3]
Related
angiotensin II receptor type 2 & 4-inhibiting antihypertensive
angiotensin II receptor type 2 & 4-stimulating antihypertensive
General
angiotensin-2 receptor
Properties
SIZE: entity length = 363 aa
MW = 41 kD
COMPARTMENT: cellular membrane
MOTIF: exoplasmic domain {1-45}
MOTIF: N-glycosylation site {N4}
N-glycosylation site {N13}
N-glycosylation site {N24}
N-glycosylation site {N29}
N-glycosylation site {N34}
cysteine residue {C35}
MODIFICATION: cysteine residue {C290}
transmembrane domain {46-71}
cytoplasmic loop {72-80}
transmembrane domain {81-102}
exoplasmic loop {103-119}
MOTIF: cysteine residue {C117}
MODIFICATION: cysteine residue {C195}
transmembrane domain {120-140}
cytoplasmic loop {141-160}
transmembrane domain {161-179}
exoplasmic loop {180-208}
MOTIF: cysteine residue {C195}
MODIFICATION: cysteine residue {C117}
transmembrane domain {209-234}
cytoplasmic loop {235-256}
transmembrane domain {257-278}
exoplasmic loop {279-297}
MOTIF: cysteine residue {C290}
MODIFICATION: cysteine residue {C35}
transmembrane domain {298-318}
cytoplasmic domain {319-363}
Database Correlations
OMIM 300034
MORBIDMAP 300034
UniProt P50052
Pfam PF00001
Entrez Gene 186
Kegg hsa:186
References
- UniProt :accession P50052
- GeneReviews
https://www.genecards.org/cgi-bin/carddisp.pl?gene=AGTR2
- Rice AS et al
EMA401, an orally administered highly selective angiotensin II
type 2 receptor antagonist, as a novel treatment for
postherpetic neuralgia: a randomised, double-blind, placebo-
controlled phase 2 clinical trial.
The Lancet, Early Online Publication, 5 February 2014
PMID: 24507377
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2962337-5/abstract